Caprelsa (vandetanib) — Medica
Thyroid carcinoma, differentiated
Initial criteria
- Patient is age ≥ 18 years
- Patient has differentiated thyroid carcinoma (e.g., papillary, follicular, oncocytic carcinoma [formerly Hürthle cell carcinoma])
- Disease is refractory to radioactive iodine therapy
Reauthorization criteria
- Patient continues to meet initial criteria
Approval duration
1 year